105 results about "Intestinal mucosal barrier" patented technology

The invention provides a spleen and stomach conditioning factor lactobacillus reuteri obtained by fermenting poria cocos powder. The strain has good acid resistance, cholate resistance and antibacterial ability. The invention further provides a probiotic preparation which has an obvious effect on improving the spleen and the stomach. In addition, the invention also provides a composite preparation composition containing Lactobacillus reuteri, and the composition effectively promotes normal peristalsis and digestion and absorption functions of gastrointestinal tracts by regulating the secretion level of gastrointestinal hormones, enhances the immunity of the organism, protects intestinal mucosa barriers, comprehensively improves the symptoms of weakness of the spleen and the stomach, and improves the overall health level.

The invention relates to a Kluyveromyces marxianus strain with high protein yield and application of the Kluyveromyces marxianus strain, which is characterized in that the Kluyveromyces marxianus strain is firstly cultured on a slant, then is transferred into a seed culture medium for seed preparation, and then is inoculated into a fermentation tank, and yeast protein is obtained by adopting index feeding; the bacterial strain is a dominant mutant strain Kluyveromyces marxianus YWX-1, the protein content in a dry thallus reaches 55% or above and is increased by 26% or above compared with that of an original bacterial strain, the bacterial strain can be used for production of single-cell protein, the essential amino acid index (EAAI) value in the protein reaches 1.2, and the bacterial strain is rich in arginine, threonine and lysine and can be applied to production of single-cell protein. These amino acids play a key role in immune regulation, intestinal mucosal barrier function and muscle protein synthesis of young animals. The YWX-1 kluyveromyces marxianus strain has a wide application prospect in the production of neoplasm protein.

The invention relates to the technical field of biomedicine, in particular to an umbilical cord mesenchymal stem cell exosome and a preparation method and application thereof.The umbilical cord mesenchymal stem cell exosome is derived from umbilical cord mesenchymal stem cells expressing S100g-MTOR binding domain fusion protein and can inhibit excessive autophagy through an S100g / MTOR signal channel, and therefore intestinal mucosal barrier damage caused by antibiotics is relieved. The preparation method comprises the following steps: constructing an expression vector, transfecting and screening a stable expression cell strain, performing serum-free culture, collecting a culture supernatant, purifying the exosome and the like. The exosome disclosed by the invention can be used for preparing a medicine for treating antibiotic-related intestinal mucosal barrier injury, has the advantages of strong targeting property, definite action mechanism, remarkable curative effect and the like, and provides a new choice for preventing and treating antibiotic-related intestinal adverse reactions.

The invention relates to the technical field of aquaculture fish vaccines, in particular to a fusion gene of grass carp NPM1a and II type reovirus VP38, recombinant protein, a composition and application. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1. The fusion gene is obtained by connecting grass carp NPM1a and II type reovirus VP38 through a linker sequence, a BamH restriction enzyme cutting site is added to the 5'end of the fusion sequence, and an XhoI restriction enzyme cutting site is added to the 3 'end of the fusion sequence; the sequence of the linker is as shown in SEQ ID NO: 2. The subunit vaccine of the fusion protein of the grass carp NPM1a and the II type reovirus VP38 is prepared, and indole-3-lactic acid is used as an immunopotentiator in a combined manner, so that the technical bottlenecks of low protection rate, poor intestinal mucosal barrier repairability and the like of the existing vaccine are overcome.

The invention belongs to the field of biological medicines, and particularly discloses application of uridine in preparation of medicines for preventing and treating ulcerative colitis, including application of uridine in preparation of medicines for preventing and treating ulcerative colitis in acute stage, application of uridine in preparation of medicines for preventing and treating ulcerative colitis in remission stage and the like. Uridine can improve the symptoms of DSS-induced acute experimental colitis model mice, has a good treatment effect, and improves the weight of the model mice; experimental results indicate that a high-dose group of uridine has a good treatment effect, the mechanism and specificity of uridine up-regulate expression and activity of colon local SIRT1 protein, further inhibit phosphorylation activation of an NF-kappa B signal channel, regulate secretion of inflammatory factors and expression of tight junction protein, repair intestinal mucosal barrier while moderately regulating immunity, and improve the immunity of a human body. The systemic inflammatory response is effectively relieved.

The invention discloses a plant lactobacillus Kimate-F, a plant lactobacillus Kimate-6, a composite probiotic composition composed of the plant lactobacillus Kimate-F and the plant lactobacillus Kimate-6, and an application of the composite probiotic composition in relieving dog transportation stress and improving dog enteritis. The probiotic composition can effectively relieve dog transportation stress and remarkably reduce indexes such as corticosterone and active oxygen. In addition, the probiotic composition can effectively prevent or relieve canine enteritis, promote reproduction of beneficial bacteria in intestinal flora, inhibit proliferation of potential harmful bacteria, repair intestinal mucosal barrier and reduce inflammatory response. The invention has a wide application prospect, is especially suitable for dogs with long-distance transportation, stress susceptibility and poor intestinal function, and can also be used in cooperation with other conventional treatment means.

The present invention relates to the field of feed, and in particular to a feed additive for preventing diarrhea in young ruminants and its application in liquid feed and solid feed. The composition provided by the present invention comprises 5-10wt.% of flavonoids, 5-10wt.% of plant essential oils and 80-90wt.% of yeast cell wall polysaccharides. The composition of the present invention is formulated with flavonoids, plant essential oils and yeast cell wall polysaccharides, and prevents the occurrence of calf diarrhea by regulating the calf's immune system, intestinal mucosal barrier system and intestinal microbial system, improving the calf's body immunity, enhancing the intestinal mucosal barrier function and promoting the balance of intestinal flora, thereby achieving the purpose of promoting the growth and development of calves and healthy cultivation.

The invention belongs to the field of pet food processing, and relates to a functional pet food for regulating intestinal health and a preparation method thereof. The functional pet food can increase MTL content in dog serum in a physiological range, reduce DAO activity and D-lactic acid and LPS content in dog serum, improve intestinal mucosa barrier function, and significantly improve dog intestinal health. The functional pet food can shorten gastrointestinal transmission time and effectively improve constipation. The functional pet food disclosed by the invention has a good effect in the aspects of treating diarrhea and constipation, and has a two-way regulation effect in regulating intestinal flora imbalance. The components of the raw materials have a synergistic effect, the nutrition is balanced, the preparation method is simple, the palatability is optimally designed, and the metabolic characteristic is free of burden, so that pets can safely take the feed for a long time, a convenient and efficient preventive health management scheme is provided for family pet raising, and the feed has a relatively good commercial application prospect.

The invention relates to a composition for regulating intestinal microenvironment and relaxing bowel and a preparation method thereof, and belongs to the technical field of biology. The composition comprises the following components in specific parts: artichoke-siraitia grosvenorii-fructus cannabis composite extract peptide, bacillus coagulans-lactobacillus reuteri calcium alginate microspheres, escherichia coli bacteriocin, salmonella bacteriocin, a liquorice extract, a semen cassiae extract, a herba cistanche extract, a dendrobium officinale extract and the like. Wherein the artichoke-siraitia grosvenorii-fructus cannabis compound extract peptide, bacillus coagulans-lactobacillus reuteri calcium alginate microspheres, the liquorice extract, the semen cassiae extract, the herba cistanche extract and the dendrobium officinale extract are obtained by a special preparation method. Through cooperation of the components, the intestinal microenvironment can be adjusted from multiple angles, and the comprehensive effects of improving the intestinal flora structure, inhibiting harmful bacteria, promoting the growth of beneficial bacteria, lubricating the intestinal tract, relieving intestinal inflammation, enhancing the intestinal mucosal barrier function, improving the intestinal immunity and the like are achieved.

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

The invention relates to the field of medicines, in particular to application of schisandrin B in preparation of medicines for preventing or treating intestinal radiation injury. The invention finds the protective effect of the schisandrin B on the irradiated intestinal tract, and experiments prove that the schisandrin B can reduce the pathological injury degree of the irradiated intestinal tract, including increasing the villus length of the intestinal tract and the number of crypts, maintaining the stability of the intestinal mucosal barrier, reducing the inflammatory factor content of the intestinal tract tissue, and improving the intestinal tract tissue. The activity of the irradiated intestinal epithelial cells is recovered, and the apoptosis of the intestinal epithelial cells is inhibited. Meanwhile, schisandrin B can relieve ferroptosis caused by irradiation. Therefore, the schizandrin B has a wide application prospect in treatment of the radioactive intestinal injury and drug development as a potential radiation protective agent.

The invention belongs to the technical field of biological medicines, and particularly relates to bacillus velezensis and application thereof in preventing and treating inflammatory bowel diseases. The bacillus velezensis GFZF-23 provided by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the bacillus velezensis GFZF-23 is CCTCC (China Center for Type Culture Collection) NO: M 20251699. The bacillus velezensis GFZF-23 can be used for effectively treating the inflammatory bowel disease by reducing the pathological injury of intestinal tissues, reducing the expression of inflammatory factors and immune receptor genes, enhancing the expression of related genes of intestinal mucosal barriers and remodeling the balance of intestinal flora. The invention provides a new treatment strategy for treating the inflammatory bowel disease, and has remarkable clinical application value and wide market prospect.

The invention relates to the field of probiotics, in particular to application of monoform megamonas in preparation of a composition for degrading phytic acid. The invention discovers that the Megamonas simplex DSM 19343 has a better degradation effect on phytic acid in vitro and in vivo, and can be used as a probiotic to degrade phytic acid in intestinal tracts into acetic acid and propionic acid, so that the intestinal mucosal barrier is protected, and the intestinal absorption of nutrient substances such as mineral substances and the like is indirectly promoted.

The invention discloses a composition for preventing and / or treating alcoholic liver diseases, a product and application thereof. The present invention relates to a composition comprising: breast milk oligosaccharides and vitamins; the breast milk oligosaccharide comprises fucosyllactose and sialic acid lactose; the composition can provide nutritional support for patients with alcoholic liver diseases, repair intestinal mucosal barrier, reduce endotoxin entering blood, improve abundance of beneficial bacteria in intestinal tracts and reduce inflammatory response, so as to achieve the purpose of preventing and / or treating alcoholic liver diseases induced by alcohol.

The present application relates to the field of medicine, and particularly to the application of schisantherin B in the preparation of a medicine for preventing or treating radiation damage of the intestinal tract. The present application finds that schisantherin B has a protective effect on the intestinal tract after irradiation, and experiments prove that schisantherin B can reduce the pathological damage degree of the intestinal tract after irradiation, including increasing the length of intestinal villi and the number of crypts, maintaining the stability of the intestinal mucosal barrier, reducing the content of inflammatory factors in the intestinal tissue, restoring the activity of the intestinal epithelial cells after irradiation, and inhibiting the apoptosis. Meanwhile, schisantherin B can reduce the iron death caused by irradiation. Therefore, schisantherin B has a wide application prospect as a potential radiation protection agent in the treatment of radiation-induced intestinal injury and drug development.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine composition for treating damp turbidity and blood stasis type hyperuricemia or gout and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 12-18 parts of radix paeoniae alba, 12-18 parts of yam rhizome, 45-55 parts of rhizoma smilacis glabrae, 25-35 parts of plantain herb, 8-12 parts of radix polygonati officinalis, 8-12 parts of radix cyathulae, 8-12 parts of fructus psoraleae, 7-11 parts of ground beeltle and 3-7 parts of liquorice. The traditional Chinese medicine composition is formulated according to the traditional Chinese medicine pathogenesis characteristics of hyperuricemia and gout, the whole formula takes improvement of intestinal mucosa barrier as the core, the effects of reducing the blood uric acid level, relieving symptoms and conditioning the body are achieved through diuresis promoting, turbidity removing, collateral dredging and blood stasis removing, and the traditional Chinese medicine composition is suitable for gout and hyperuricemia caused by intestinal damp turbidity and blood stasis blocking.

The invention discloses a copper ion-kaempferol nano-composite and application thereof in treatment of inflammatory bowel disease, the obtained nano-composite has very strong stability and active oxygen scavenging ability, and has excellent oxidation resistance and anti-inflammatory ability, and the specific performance is as follows: the surface is negatively charged, and the nano-composite can specifically target the diseased region of intestinal inflammation, so that the copper ion-kaempferol nano-composite can be applied to treatment of inflammatory bowel disease. The intestinal mucosal barrier injury is effectively repaired, the imbalance state of intestinal flora is adjusted, and the intestinal inflammation microenvironment is remarkably improved; the antioxidant and anti-inflammatory capacities of cells can be enhanced by regulating and controlling a PI3K-Akt signal channel and a nuclear factor kappa B (NF-kappa B) signal channel; the compound shows an excellent treatment effect in mouse models of typical inflammatory bowel diseases such as ulcerative colitis and Crohn's disease and related complications of bowel diseases. The invention provides a new way for constructing a multi-target and multi-layer treatment platform for the inflammatory bowel disease of a natural product.

The invention provides application of an Slc36a1 agonist in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of biology. According to the invention, 4-GBA or sarcosine is applied to a colitis model mouse, and clinical and histological phenotypes of DSS-induced colitis can be significantly improved. According to experiments of colonic organs and mice, 4-GBA enhances intestinal mucosal barrier and promotes intestinal homeostasis by up-regulating Slc36a1. According to the invention, 4-GBA or sarcosine molecules targeting Slc36a1 are taken as a core, and the limitation of an existing treatment strategy is broken through by synchronously solving a linkage mechanism of stem cell regeneration-goblet cell differentiation-mucous barrier repair.

The invention relates to the technical field of biological medicine, and discloses application of a GLS1 inhibitor BPTES in relieving ulcerative colitis and a medicine for relieving ulcerative colitis, and the active ingredient of the medicine comprises BPTES. The invention proves that the inhibitor BPTES of the glutaminase 1 (GLS1) can obviously relieve clinical symptoms of mouse ulcerative colitis, improve intestinal mucosal barrier damage, reduce the level of inflammation in a mouse body and inhibit excessive activation of a Wnt / beta-catenin signal channel; likewise, the regulation of glutamine metabolism is expected to become a new treatment direction of UC.

The invention discloses application of chlorogenic acid in preparation of a product with functions of protecting intestinal mucosa and regulating intestinal flora, and belongs to the technical field of medical health care products. Animal experiments prove that the chlorogenic acid can effectively relieve intestinal mucosa barrier damage caused by hypoxia, reverse abnormal increase of alpha-diversity of intestinal bacteria and optimize the flora structure in allusion to the fact that the regulation effect of the chlorogenic acid on the intestinal mucosa damage and intestinal flora disorder induced by hypoxia is not involved in the prior art. The product is suitable for preventing and treating intestinal mucosal barrier damage and intestinal microecological imbalance caused by acute and chronic hypoxia or drug stimulation.

The invention discloses six probiotics for preventing severe heatstroke and application of the six probiotics. A probiotic composition is prepared from bacillus coagulans XY2, lactobacillus plantarum KL100, lactobacillus rhamnosus TR08, lactobacillus helveticus TR05, lactobacillus casei TR01 and bifidobacterium longum TR17. The invention discloses novel application of the probiotic composition in prevention of severe heatstroke, heatstroke combined with liver injury, enhancement of intestinal mucosal barrier function, heatstroke combined with lung injury and heatstroke combined with myocardial injury. The sextuple probiotic preparation can effectively protect the state of an organism, enhance the resistance of the organism to high temperature, maintain the balance of a body temperature regulation mechanism, and prevent or relieve the phenomenon of severe heatstroke of the organism, and has the effects of preventing severe heatstroke and relieving heatstroke combined liver injury, lung injury and myocardial injury. Meanwhile, the six probiotic preparations can effectively enhance the intestinal mucosal barrier, and a new method and thought are provided for preventing the adverse outcome of extreme high temperature and complications thereof.

The invention discloses application of retinaldehyde dehydrogenase activating peptides derived from three euphausia superba in prevention or treatment of radiotherapy intestinal side reactions, and belongs to the technical field of bioactive peptides. The euphausia superba-derived retinaldehyde dehydrogenase activating peptides have three kinds of amino acid sequences, and the amino acid sequences of the retinaldehyde dehydrogenase activating peptides are respectively shown as SEQ ID NO.1-3. The euphausia superba-derived retinaldehyde dehydrogenase activating peptide is applied to prevention or treatment of radiotherapy intestinal side reactions. According to the invention, three potential retinaldehyde dehydrogenase activated peptides are identified from the antarctic krill protein peptide sequence by using high-resolution mass spectrometry, and the effect of the retinaldehyde dehydrogenase activated peptides on preventing or treating radiotherapy intestinal side reactions is verified by using animal experiments. Results show that three small molecule peptides can improve weight loss and intestinal structure damage caused by radiation, thereby repairing intestinal mucosal barriers and improving side effects of radiotherapy intestinal tracts.

The application relates to the technical field of medicines, in particular to application of N-acetylneuraminic acid in preparation of medicines for preventing and / or treating ulcerative colitis. The application finds that N-acetylneuraminic acid can effectively prevent or treat ulcerative colitis and promote tissue repair by regulating macrophage metabolism, inhibiting glycolysis pathways and M1 type polarization, and simultaneously repairing intestinal mucosal barrier, thereby providing a safe, simple and clear mechanism of action new treatment strategy for clinic.

The invention discloses a polyphenol-calcium phosphate-hyaluronic acid multifunctional probiotic delivery carrier with an adjustable structure and a preparation method of the polyphenol-calcium phosphate-hyaluronic acid multifunctional probiotic delivery carrier. The carrier is constructed by regulating calcium phosphate mineralization through polyphenol to form a flower-like structure and then adsorbing hyaluronic acid. The preparation method comprises the following steps: (1) preparing nanoflowers from polyphenol chelated calcium phosphate; (2) in-situ packaging of probiotics by the nanoflowers; and (3) coating the probiotic carrier with hyaluronic acid. The preparation method is simple in process and mild in condition, the prepared probiotic packaging body is excellent in biocompatibility, not only can improve gastrointestinal fluid environment tolerance, but also has the capabilities of active oxygen removal, inflammation targeting and intestinal colonization, and by synergistically reducing colitis, relieving tissue damage, repairing intestinal mucosal barrier and restoring intestinal flora balance, the intestinal tract intestinal colonization effect is improved. A new strategy is provided for the treatment of the inflammatory bowel disease.

The invention relates to application of an indole base compound in preparation of a medicine for treating or preventing intestinal diseases. The intestinal diseases are related diseases caused by abnormity of a high-level serotonin trigger signal channel. According to the invention, active molecules for specific regulation and control of serotonin signals of blood and intestinal tracts are screened, and the indoline can lower intestinal inflammation damage and promote intestinal mucosal barrier; the anti-tumor immunity can also be promoted. And the medicine has the characteristic of high safety while playing a treatment role.

The invention discloses bacillus velezensis and application thereof in relieving fish intestinal injury induced by high cottonseed meal feed, and relates to the technical field of aquaculture, the classification name of the strain is bacillus velezensis GCB-2, the strain is preserved in the China General Microbiological Culture Collection Center on January 7, 2026, and the preservation number is CGMCC NO.37317. The invention further discloses a preparation method of the bacillus velezensis. According to the bacillus velezensis GCB-2 disclosed by the invention, fish intestinal injury induced by high cottonseed meal feed can be relieved; after the strain is added into fish feed, the growth performance of fishes can be remarkably improved, intestinal oxidative damage and inflammatory response caused by high-cottonseed-meal feed can be effectively relieved, and meanwhile the effects of repairing intestinal mucosal barriers and adjusting intestinal flora balance are achieved so as to improve intestinal health.

The application discloses application of forskolin and / or isoforskolin in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of medicines.The medicine can significantly improve the disease phenotype of colitis, including relieving weight loss, reducing disease activity index score, improving colon length shortening and histopathological damage.The mechanism of action involves multiple targets: repairing intestinal mucosal barrier function, reducing local inflammation of the colon, and regulating intestinal flora balance, restoring the abundance of beneficial bacteria and inhibiting the proliferation of pathogenic bacteria.The application provides a candidate drug with anti-inflammatory, barrier repair and flora regulation functions for the treatment of colitis, and expands the medical use of forskolin or isoforskolin.

The application belongs to the technical field of biological medicine, and particularly relates to a medium-chain fatty acid composition for improving immunity of calves and a preparation method thereof. The medium-chain fatty acid composition for improving immunity of calves according to the application comprises, in terms of weight fractions, 20-30 parts of lactose, 5-10 parts of medium-chain fatty acid, 1-3 parts of mangiferin derivative, 0.5-2 parts of wedelolactone and 0.2-1 part of vitamin C. The mangiferin derivative according to the application can relieve local inflammatory reaction of the intestinal tract, repair the intestinal mucosal barrier damaged by stress, and enhance the non-specific immune capacity of the body. The wedelolactone according to the application forms a double synergy with the lactose and the medium-chain fatty acid, greatly improves the utilization efficiency of energy and nutrients, and thus promotes the growth and development of the calf. In addition, the wedelolactone can also synergize with the mangiferin derivative, maintains the intestinal health of the calf in the early weaning period, and significantly weakens the weaning stress impact.

The invention discloses application of a composition containing a cordyceps militaris extract to preparation of a product for preventing and treating colitis. The composition comprises the cordyceps militaris extract, an astragalus extract, a sanguisorba officinalis extract and a rhizoma bletillae extract. The composition provided by the invention aims to relieve swelling and pain, nourish yin and clear heat, and tonify spleen and warm kidney, promotes intestinal mucosal barrier repair, quickly relieves inflammatory response, and cures or improves colitis.